Literature DB >> 23769424

Associations between pain clinic density and distributions of opioid pain relievers, drug-related deaths, hospitalizations, emergency department visits, and neonatal abstinence syndrome in Florida.

Erin K Sauber-Schatz1, Karin A Mack, Shane T Diekman, Leonard J Paulozzi.   

Abstract

BACKGROUND: Community-level associations between pain clinics and drug-related outcomes have not been empirically demonstrated.
METHODS: To explore these associations we correlated overdose death rates, hospital-discharge rates for drug-related hospitalizations including neonatal abstinence syndrome, and emergency department rates for drug-related visits with registered pain clinic density and rate of opioid pills dispensed per person at the county-level Florida in 2009. Negative binomial regression was used to model the crude associations and associations adjusted for exposure measures and county demographic characteristics.
RESULTS: An estimated 732 pain clinics operated in Florida in 2009, a rate of 3.9/100,000 people. Among the 67 counties in Florida, 23 (34.3%) had no pain clinics, and three had 90 or more. Adjusted negative binomial regression determined no significant association between pain clinic rate and drug-related outcomes. However, rates of drug-caused, opioid-caused, and oxycodone-caused death correlated significantly with rates of opioid and oxycodone pills dispensed per person in adjusted analyses. For every increase of one pill in the rate of oxycodone pills per person, there was a 6% increase in the rate of oxycodone-related overdose death.
CONCLUSIONS: Although pain clinics, some of which are "pill mills," are clearly a source of drugs used nonmedically, their impact on health outcomes might be difficult to quantify because the pills they prescribe might be consumed in other counties or states. The impact of "pill mill" laws might be better measured by more proximal measures such as the number of such facilities. Published by Elsevier Ireland Ltd.

Entities:  

Keywords:  Drug overdose death; Drug-related hospitalization; Florida; Neonatal abstinence syndrome; Pain clinic; Pill mill

Mesh:

Substances:

Year:  2013        PMID: 23769424     DOI: 10.1016/j.drugalcdep.2013.05.017

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  12 in total

1.  Opioid Prescribing for the Treatment of Acute Pain in Children on Hospital Discharge.

Authors:  Constance L Monitto; Aaron Hsu; Shuna Gao; Paul T Vozzo; Paul S Park; Deborah Roter; Gayane Yenokyan; Elizabeth D White; Deepa Kattail; Amy E Edgeworth; Kelly J Vasquenza; Sara E Atwater; Joanne E Shay; Jessica A George; Barbara A Vickers; Sabine Kost-Byerly; Benjamin H Lee; Myron Yaster
Journal:  Anesth Analg       Date:  2017-12       Impact factor: 5.108

2.  Drug overdose surveillance using hospital discharge data.

Authors:  Svetla Slavova; Terry L Bunn; Jeffery Talbert
Journal:  Public Health Rep       Date:  2014 Sep-Oct       Impact factor: 2.792

3.  Effect of a "pill mill" law on opioid prescribing and utilization: The case of Texas.

Authors:  Tatyana Lyapustina; Lainie Rutkow; Hsien-Yen Chang; Matthew Daubresse; Alim F Ramji; Mark Faul; Elizabeth A Stuart; G Caleb Alexander
Journal:  Drug Alcohol Depend       Date:  2015-12-31       Impact factor: 4.492

4.  Impact of prescription drug monitoring programs and pill mill laws on high-risk opioid prescribers: A comparative interrupted time series analysis.

Authors:  Hsien-Yen Chang; Tatyana Lyapustina; Lainie Rutkow; Matthew Daubresse; Matt Richey; Mark Faul; Elizabeth A Stuart; G Caleb Alexander
Journal:  Drug Alcohol Depend       Date:  2016-06-02       Impact factor: 4.492

5.  Prevalence of prescription medication use among non-pregnant women of childbearing age and pregnant women in the United States: NHANES, 1999-2006.

Authors:  Sarah C Tinker; Cheryl S Broussard; Meghan T Frey; Suzanne M Gilboa
Journal:  Matern Child Health J       Date:  2015-05

6.  Comparison of Crude Population-Level Indicators of Opioid Use and Related Harm in New Zealand and Ontario (Canada).

Authors:  Benedikt Fischer; Dimitri Daldegan-Bueno; Wayne Jones
Journal:  Pain Ther       Date:  2020-12-31

7.  The effect of an abuse-deterrent opioid formulation (OxyContin) on opioid abuse-related outcomes in the postmarketing setting.

Authors:  P M Coplan; H D Chilcoat; S F Butler; E M Sellers; A Kadakia; V Harikrishnan; J D Haddox; R C Dart
Journal:  Clin Pharmacol Ther       Date:  2016-06-22       Impact factor: 6.875

8.  Prescription opioid use, illicit drug use, and sexually transmitted infections among participants from a community engagement program in North Central Florida.

Authors:  Abenaa B Acheampong; Catherine W Striley; Linda B Cottler
Journal:  J Subst Use       Date:  2016-05-25

9.  Vital signs: variation among States in prescribing of opioid pain relievers and benzodiazepines - United States, 2012.

Authors:  Leonard J Paulozzi; Karin A Mack; Jason M Hockenberry
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2014-07-04       Impact factor: 17.586

10.  Reductions in reported deaths following the introduction of extended-release oxycodone (OxyContin) with an abuse-deterrent formulation.

Authors:  Nelson E Sessler; Jerod M Downing; Hrishikesh Kale; Howard D Chilcoat; Todd F Baumgartner; Paul M Coplan
Journal:  Pharmacoepidemiol Drug Saf       Date:  2014-06-11       Impact factor: 2.890

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.